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Abstract: We compared the results and differences of indeterminate rates between the QuantiFERON-
TB Gold In-Tube (QFT-GIT) and QuantiFERON-TB Gold PLUS (QFT-PLUS) tests in patients with
rheumatic diseases and analyzed the associated factors. Data of patients with rheumatic diseases
who had undergone the QFT-GIT or QFT-PLUS test were used, and information regarding patient
demographics, primary diagnosis, laboratory results, and medications was collected. Furthermore,
indeterminate result rates of the patient cohort and healthy controls were also compared. A total
of 177 (43.4%) and 231 (56.6%) patients had undergone QFT-GIT and QFT-PLUS tests, respectively.
Among them, four (2.3%) and seven (3.0%) patients had indeterminate results, which did not differ
between the QFT-GIT and QFT-PLUS groups. Indeterminate results were significantly higher among
patients with rheumatic diseases than in healthy controls (2.7% vs. 0.2%, p < 0.001). Multivariate
logistic regression revealed that the lymphocyte count (hazard ratio (HR) 0.998, 95% confidence
interval (CI) 0.997, 1.000; p = 0.012) and albumin level (HR 0.366, 95% CI 0.150, 0.890; p = 0.027) were
predictive of indeterminate results. A lymphocyte count of ≤810/mm3 and an albumin level of
≤3.7 mg/dL were capable of discriminating between indeterminate and determinate results. The
QFT-GIT and QFT-PLUS tests have comparable diagnostic performances in patients with rheumatic
diseases. Decreased lymphocyte and albumin levels contribute to indeterminate results.
Keywords: QuantiFERON-TB Gold In-Tube; QuantiFERON-TB Gold PLUS; rheumatic diseases;
indeterminate; factors
1. Introduction
Tuberculosis (TB) is a highly contagious disease caused by Mycobacterium tuberculosis
(MTB) infection and is a substantial public health burden. Given that more than 10 million
people are affected with TB annually, it stands as one of the leading causes of death
worldwide [1]. Latent tuberculosis infection (LTBI) is defined as being infected with MTB
in the absence of active signs and symptoms of TB. This is considered a major risk factor for
developing active TB [2]; therefore, appropriate screening of LTBI in high-risk individuals
is considered crucial in preventing the community transmission of TB. An interferon-
gamma release assay (IGRA) is a laboratory test used to diagnose LTBI by measuring
the release of inflammatory cytokines, such as interferon-γ (IFN-γ), after mycobacterial
antigen exposure [3]. After the first approval of TSPOT.TB as a commercially available
IGRA in 2004, QuantiFERON-TB (QFT) Gold was adopted for clinical use in 2005 and is
now being widely used in medical practice for LTBI screening. In particular, advanced
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new generation QFT tests—QuantiFERON-TB Gold In-Tube (QFT-GIT) and QuantiFERON-
TB Gold PLUS (QFT-PLUS) tests—have been developed and used in clinical settings [4].
The QFT-PLUS test, which was approved by the FDA in 2017, is the latest QFT assay.
The main difference between the QFT-PLUS and QFT-GIT tests is that two TB antigen
tubes, TB1 and TB2, are utilized to measure the CD4+ T cell and CD8+ T cell immune
responses, respectively, in the former. The individual evaluation of CD4+ and CD8+ T
cell IFN-γ production is thought to help in assessing adaptive immunity more precisely
than that with a combined evaluation [5]. Notably, the literature has suggested that the
QFT-PLUS test correlates well with the previous version of the QFT test while having
an improved diagnostic performance, particularly in terms of sensitivity and specificity.
Additionally, it is preferred for immunocompromised patients such as those with human
immunodeficiency virus (HIV) infection [6–8].
The underlying pathogenesis of rheumatic diseases is characterized by the develop-
ment of aberrant immunity [9]. Consequently, the unbalanced pro- and anti-inflammatory
immune response is a typical feature of rheumatic diseases, and therapeutic agents gener-
ally target excessive inflammation. Previous studies have demonstrated that indeterminate
IGRA results can be found in the presence of altered immunity or the use of immuno-
suppressive drugs [10–12]. Thus, it was suggested that indeterminate results are more
frequently reported in patients with rheumatic diseases. A single-center study that evalu-
ated the prevalence of indeterminate rates using QFT-GIT tests showed that the overall
frequency of an indeterminate IGRA was 6.8% [13]. Conversely, an analysis of patients
tested using QFT-GIT tests in a large United States health system reported that indeter-
minate results were found in 5.3% of patients with chronic inflammatory disease, and
these patients were 2.4 times more likely to have indeterminate results than hospital
employees [14].
Given that QFT-PLUS tests, which comprise four tubes to measure IFN-γ, measure
helper and cytotoxic T cell responses separately and have a distinct standard to define
indeterminate results compared to those QFT-GIT tests, it is possible that the diagnostic
performance of the two assays could differ in patients with rheumatic diseases. However,
to the best of our knowledge, no study on this has been conducted. Additionally, the
influence of clinical and laboratory parameters associated with indeterminate results is still
inconclusive in this population. Therefore, this study aimed to analyze whether there is
a difference in indeterminate rates among patients with rheumatic diseases tested with
QFT-GIT and QFT-PLUS tests and the factors affecting these results.
2. Materials and Methods
2.1. Data Collection
This retrospective analysis was performed using data of patients who underwent
QFT-GIT and QFT-PLUS tests at Severance Hospital during the period of April 2018 to
March 2019. In Severance Hospital, the QFT-GIT test was utilized to diagnose LTBI until
September 2018, and the QFT-PLUS test was introduced after October 2018. During this
period, 4253 patients with IGRA data were identified from the hospital’s Clinical Data
Repository System. These included 424 patients with a primary diagnosis of rheuma-
toid arthritis (RA), ankylosing spondylitis, Behçet disease, systemic lupus erythematosus
(SLE), adult-onset Still’s disease, anti-neutrophil cytoplasmic antibody-associated vasculitis
(either microscopic polyangiitis, granulomatosis with polyangiitis, or eosinophilic gran-
ulomatosis with polyangiitis), polyarteritis nodosa, psoriatic arthritis, dermatomyositis
(DM) or polymyositis, polymyalgia rheumatica, systemic sclerosis, and immunoglobulin
G4-related disease. After reviewing medical records, it was found that 16 patients had a
diagnosis unrelated to or incomplete for diagnosing the rheumatic diseases investigated.
Finally, a total of 408 patients were included in the study (Figure 1).
This study was approved by the Severance Hospital Institutional Review Board
(4-2021-0353), and all relevant procedures were performed in accordance with the Declara-
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tion of Helsinki. The requirement to obtain informed consent from the patients was waived
as this was a retrospective study.
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Figure 1. Patient selection and exclusion. QFT-GIT: QuantiFERON-TB Gold In-Tube; QFT-PLUS:
QuantiFERON-TB Gold PLUS.
2.2. Analysis of Patient Data and Medication
Patient data consisted of age, sex, primary diagnosis, laboratory data at the date of
QFT-GIT or QFT-PLUS testing, and the results of the IGRA. Laboratory data consisted
of white blood cell, neutrophil, lymphocyte, and platelet counts, as well as hemoglobin,
blood urea nitrogen, creatinine, albumin, aspartate aminotransferase, alanine aminotrans-
ferase (ALT), and C-reactive protein (CRP) levels and erythrocyte sedimentation rate
(ESR). Information on medications—glucocorticoid, methotrexate, hydroxychloroquine,
sulfasalazine, tacrolimus, leflunomide, 5-acetylsalicylic acid, azathioprine, mycopheno-
late mofetil, cyclophosphamide, cyclosporine, biologic and targeted synthetic disease-
modifying antirheumatic drugs—that the patients were being administered for disease
control was also collected by a retrospective chart review.
2.3. QFT-GIT and QFT-PLUS Assay and Healthy Controls
Both the QFT-GIT and QFT-PLUS (Qiagen, Hilden, Germany) tests were performed
according to the instructions provided by the manufacturer using a standa dized pro ocol
in the Department of Laboratory Medicine, Division of Diag ostic Immunology. Inte -
pretation of IGRA results was conducted as described previously [15]. The South Korean
government mandates healthcare-rel ted professionals working in h spitals to undergo
testing using an IGRA to evaluate the presence of LTBI before employment. T e results of
the IGRA from individuals who were subject to the employment check-up were utilized to
evaluate the difference in indeterminate rates between patients with rheumatic diseases
and healthy controls. Data one year prior to the introduction of the QFT-PLUS test (by
QFT-GIT, n = 2511) and data one year after the adoption of the QFT-PLUS test (n = 1614)
were analyzed.
2.4. Statistical Analysis
All statistical analyses were conducted using MedCalc version 19.6.4 (MedCalc Soft-
ware, Ostend, Belgium). Continuous variables are represented as mean ± standard devia-
tion, whereas categorical variables are shown as frequencies and percentages. Statistical
differences between continuous variables were evaluated by Student’s t-test, while com-
parison of categorical variables was conducted utilizing a chi-square test or Fisher’s exact
test for two groups, or a chi-square test for trends in more than three groups. Multivariate
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logistic regression analysis using a forward entry method including significant variables in
the univariate analysis was conducted to evaluate factors associated with indeterminate
results. The ideal cut-off values for predicting indeterminate results were elucidated by
receiver operating characteristic (ROC) curve analysis, and calculation of the relative risk
(RR) was performed using contingency tables and a chi-square test. A two-tailed p-value
of <0.05 was considered statistically significant.
3. Results
3.1. Comparison of Patient Characteristics and Medications between the QFT-GIT and
QFT-PLUS Groups
Among the 408 patients with rheumatic diseases, 177 (43.4%) and 231 (56.6%) patients
had undergone QFT-GIT and QFT-PLUS tests, respectively. No differences were observed
with respect to age and the distribution of primary diagnoses. The frequency of males was
higher in the QFT-PLUS group than in the QFT-GIT group (39.4% vs. 29.4%, p = 0.036).
Concerning laboratory data, although the ESR was found to be elevated in the QFT-GIT
group, other parameters were comparable between the two groups. The results of the
IGRA were similar between the QFT-GIT and QFT-PLUS groups; indeterminate results
were found in 2.3% (4/177 patients) and 3.0% (7/231 patients) of patients in the QFT-GIT
and QFT-PLUS groups, respectively (Table 1).




(n = 231) p-Value
Demographics
Age (years), mean ± SD 48.9 ± 15.4 47.8 ± 15.0 0.473
Sex, n (%) 0.036
Female 125 (70.6) 140 (60.6)
Male 52 (29.4) 91 (39.4)
Primary diagnosis, n (%) 0.052
Rheumatoid arthritis 81 (45.8) 79 (34.2)
Ankylosing spondylitis 22 (12.4) 48 (20.8)
Behcet disease 21 (11.9) 33 (14.3)
Systemic lupus erythematosus 18 (10.2) 23 (10.0)
Adult-onset Still disease 13 (7.3) 6 (2.6)
Systemic necrotizing vasculitis 7 (4.0) 17 (7.4)
Psoriatic arthritis 6 (3.4) 12 (5.2)
Dermatomyositis/polymyositis 4 (2.3) 4 (1.7)
Polymyalgia rheumatica 2 (1.1) 3 (1.3)
Systemic sclerosis 2 (1.1) 2 (0.9)
IgG4-related disease 1 (0.6) 4 (1.7)
Laboratory data, mean ± SD
White blood cell count (/mm3) 7661.6 ± 3921.2 7765.2 ± 3611.6 0.782
Neutrophil count (/mm3) 5222.2 ± 3347.4 5396.9 ± 4092.6 0.636
Lymphocyte count (/mm3) 1621.8 ± 976.2 1705.8 ± 920.0 0.374
Hemoglobin (g/dL) 12.4 ± 1.9 12.6 ± 2.0 0.221
Platelet count (×1000/mm3) 276.6 ± 120.1 286.5 ± 105.1 0.378
Blood urea nitrogen (mg/dL) 16.1 ± 9.2 16.9 ± 12.9 0.462
Creatinine (mg/dL) 0.9 ± 1.4 0.9 ± 0.9 0.557
Albumin (mg/dL) 3.9 ± 0.5 4.0 ± 0.6 0.751
Aspartate aminotransferase (IU/L) 22.4 ± 13.3 29.0 ± 80.5 0.219
Alanine aminotransferase (IU/L) 19.7 ± 16.4 24.6 ± 36.7 0.072
Erythrocyte sedimentation rate (mm/h) 49.1 ± 37.1 38.5 ± 32.4 0.002
C-reactive protein (mg/L) 23.7 ± 46.1 21.8 ± 42.9 0.681
IGRA results, n (%) 0.226
Indeterminate 4 (2.3) 7 (3.0)
Positive 44 (24.9) 40 (17.3)
Negative 129 (72.9) 184 (79.7)
QFT-GIT: QuantiFERON-TB Gold In-Tube; QFT-PLUS: QuantiFERON-TB Gold PLUS; IgG4: immunoglobulin G4; SD: standard deviation;
IGRA: interferon-gamma release assay.
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When the use of medication was compared between the groups, patients in the QFT-
GIT group were more often prescribed glucocorticoids and tacrolimus than patients in the
QFT-PLUS group. However, the use of other medications did not differ significantly (Table 2).






(n = 231) p-Value
Glucocorticoid 0.040
No 76 (42.9) 124 (53.7)
Yes 101 (57.1) 107 (46.3)
Methotrexate 0.241
No 104 (58.8) 150 (64.9)
Yes 73 (41.2) 81 (35.1)
Hydroxychloroquine 0.459
No 157 (88.7) 198 (85.7)
Yes 20 (11.3) 33 (14.3)
Sulfasalazine 0.452
No 131 (74.0) 162 (70.1)
Yes 46 (26.0) 69 (29.9)
Tacrolimus 0.028
No 162 (91.5) 224 (97.0)
Yes 15 (8.5) 7 (3.0)
Leflunomide 1.000
No 151 (85.3) 197 (85.3)
Yes 26 (14.7) 34 (14.7)
5-acetylsalicylic acid 0.798
No 166 (93.8) 214 (92.6)
Yes 11 (6.2) 17 (7.4)
Azathioprine 0.524
No 171 (96.6) 219 (94.8)
Yes 6 (3.4) 12 (5.2)
Mycophenolate mofetil 1.000
No 172 (97.2) 224 (97.0)
Yes 5 (2.8) 7 (3.0)
Cyclophosphamide 1.000
No 176 (99.4) 230 (99.6)
Yes 1 (0.6) 1 (0.4)
Cyclosporine 1.000
No 174 (98.3) 228 (98.7)
Yes 3 (1.7) 3 (1.3)
bDMARDs/tsDMARDs 0.353
No 162 (91.5) 218 (94.4)
Yes 15 (8.5) 13 (5.6)
QFT-GIT: QuantiFERON-TB Gold In-Tube; QFT-PLUS: QuantiFERON-TB Gold PLUS; bDMARDS: biologic
disease-modifying antirheumatic drugs; tsDMARDs: targeted synthetic disease-modifying antirheumatic drugs.
3.2. Indeterminate IGRA Results in Patients with Rheumatic Diseases and Healthy Controls
On comparing the rates of indeterminate results between patients with rheumatic
diseases and healthy controls tested using QFT-GIT or QFT-PLUS during the employment
check-up, it was found that the rates were significantly higher in patients with rheumatic
diseases than in controls (p < 0.001, Table 3).








(n = 1614) p-Value
IGRA results, n (%) <0.001
Indeterminate 4 (2.3) 7 (3.0) 5 (0.2) 4 (0.2)
Positive/negative 173 (97.7) 224 (97.0) 2506 (99.8) 1610 (99.8)
QFT-GIT: QuantiFERON-TB Gold In-Tube; QFT-PLUS: QuantiFERON-TB Gold PLUS; RD: rheumatic diseases;
HC: healthy control.
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3.3. Patients with an Indeterminate IGRA and Factors Associated with the Occurrence of
Indeterminate Results
In total, eleven patients (2.7%) had indeterminate results. Of these, eight patients
(72.7%) were female. The primary diagnoses were SLE for four patients, RA for three
patients, and DM for three patients. There was a large variability in the laboratory data:
lymphocyte count, 30–1830 mm3; albumin level, 2.6–4.5 mg/dL; ESR, 17–120 mm/h; and
CRP level, 0.3–341.1 mg/L, and only two patients were treatment-naïve. Additionally, the
analysis of IFN-γ in separate tubes indicated that two of the patients had high IFN-γ levels
detected in the Nil tube, whereas the remaining nine cases had decreased IFN-γ levels in
the Mitogen tube (Table 4).
Table 4. Description of patient characteristics with indeterminate IGRA results.




















#1 49 F DM 71 2.6 25 40.3 mPD 40 mg,TAC, RTX QFT-GIT 0.04 0.06
#2 48 F DM 640 3.5 95 47.9 mPD 12 mg,MMF, HCQ QFT-PLUS 0.15 0.43
#3 68 M DM 710 2.7 16 8.8 PL 10 mg QFT-PLUS 0.02 0.12
#4 7 M RA 1330 3.6 31 57.6 PL 20 mg QFT-GIT 0.08 0.29
#5 54 F RA 1460 3.7 120 36.7 MTX, HCQ QFT-GIT 0.04 0.06
#6 69 F RA 720 2.3 120 341.1 None QFT-PLUS 0.04 0.44
#7 39 F SLE 650 2.6 57 62.3 None QFT-GIT 0.95 1.07
#8 36 F SLE 30 2.9 24 35.6 PL 50 mg, HCQ QFT-PLUS ≥10 ≥10
#9 37 F SLE 810 3.9 120 31.1 mPD 62.5 mg QFT-PLUS 0.09 0.25
#10 31 M SLE 1830 4.5 17 0.3 mPD 4 mg, MMF QFT-PLUS ≥10 ≥10
#11 47 F SLE 260 2.2 116 114 PL 30 mg, MMF QFT-PLUS 0.1 0.25
IGRA: interferon-gamma release assay; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IFN-γ: interferon-γ; DM: dermato-
myositis; mPD: methylprednisolone; TAC: tacrolimus; RTX: rituximab; QFT-GIT: QuantiFERON-TB Gold In-Tube; MMF: mycophenolate
mofetil; HCQ: hydroxychloroquine; QFT-PLUS: QuantiFERON-TB Gold PLUS; PL: prednisolone; RA: rheumatoid arthritis; MTX: methotrex-
ate; SLE: systemic lupus erythematosus.
In the univariate logistic regression analysis, it was determined that lymphocyte and
platelet counts, hemoglobin, albumin, ALT, and CRP levels, and ESR were associated with
an indeterminate IGRA result. The inclusion of these variables in the multivariate logistic
regression analysis revealed that only the lymphocyte count (hazard ratio (HR) 0.998, 95%
confidence interval (CI) 0.997, 1.000; p = 0.012) and albumin level (HR 0.366, 95% CI 0.150,
0.890; p = 0.027) were independent predictive factors (Table 5).
Table 5. Logistic regression analysis for factors associated with indeterminate results.
Univariate Analysis Multivariate Analysis ‡
Variables HR 95% CI p-Value HR 95% CI p-Value
Age 0.982 0.944, 1.021 0.353
Female sex 0.688 0.180, 2.636 0.586
White blood cell count 1.000 1.000, 1.000 0.461
Neutrophil count 1.000 1.000, 1.000 0.109
Lymphocyte count 0.998 0.996, 0.999 <0.001 0.998 0.997, 1.000 0.012
Hemoglobin 0.592 0.442, 0.793 <0.001
Platelet count 0.992 0.985, 0.998 0.013
Blood urea nitrogen 1.013 0.976, 1.053 0.492
Creatinine 0.936 0.483, 1.812 0.844
Albumin 0.220 0.105, 0.463 <0.001 0.366 0.150, 0.890 0.027
Aspartate aminotransferase 1.013 0.998, 1.027 0.081
Alanine aminotransferase 1.011 1.003, 1.019 0.009
Erythrocyte sedimentation rate 1.018 1.002, 1.034 0.026
C-reactive protein 1.010 1.004, 1.017 0.002
Glucocorticoid usage 2.627 0.687, 10.046 0.158
Immunosuppressive agent usage 0.372 0.111, 1.247 0.109
‡ Including statistically significant variables in univariate analysis only. HR: hazard ratio; CI: confidence interval.
3.4. Estimating Ideal Cut-Off Value of Lymphocyte Count and Albumin Levels for Discrimination
of Indeterminate Results
In the ROC curve analysis, the area under the ROC curve for a lymphocyte count
of ≤810/mm3 was 0.827 (95% CI 0.787, 0.862; p < 0.001), and for an albumin level of
≤3.7 mg/dL, it was 0.819 (95% CI 0.778, 0.855; p < 0.001), for discriminating between
indeterminate and determinate results (Figure 2).
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Figure 3. Relative risk of indeterminate results according to lymphocyte count and albumin level. Patients with (A) a
lymphocyte count of ≤810 mm3 and (B) an albumin level of ≤3.7 mg/dL had a significantly higher risk of indeterminate
results being reported than those who did not meet these criteria. In addition, the RR increased in those with both (C) a
lymphocyte count of ≤810 mm3 and an albumin level of ≤3 7 mg/dL. RR: relative risk.
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4. Discussion
An indeterminate IGRA result is commonly found in patients with rheumatic diseases,
with an immunocompromised state, or in a critically ill condition [14,16,17]. On the other
hand, indeterminate results cause significant uncertainty when making a clinical decision
on whether treatment for LTBI is required. On analyzing the data of 408 patients with
rheumatic diseases tested with QFT-QIT or QFT-PLUS, it was observed that the fourth
generation of the QFT test (the QFT-PLUS) had similar outcomes regarding indeterminate
results to those of its predecessor, the QFT-GIT test, implying that the diagnostic utility of
both assays is comparable. Additionally, in line with previous studies, we demonstrated
that indeterminate results are more frequently found in patients with rheumatic diseases
than in healthy controls. Importantly, it was also revealed that lymphocyte counts and
albumin levels are independent factors that could influence the indeterminate results of
the QFT-GIT and QFT-PLUS tests.
Despite the decreasing burden of TB in South Korea, it is still a major concern owing
to the higher rates of incidence and prevalence compared to those in Western countries.
Furthermore, LTBI was reportedly found in over 30% of the general population according
to a recent national TB statistics report [18]. In the present study, it was found that 20.6%
of patients (84 out of 408 patients) had positive IGRA results. The relatively low positive
rates of IGRAs compared to those in the general population might be attributed to the fact
that LTBI is more prevalent in males and elderly populations [19]; meanwhile, rheumatic
diseases are more frequent in females and uncommon in elderly individuals. Moreover,
we found that the overall indeterminate result rate was 2.7% in patients tested using QFT-
GIT and QFT-PLUS. However, this rate seems to be somewhat lower compared to those
reported previously. Surprisingly, among the healthcare providers (4125 individuals) who
underwent testing using IGRAs (QFT-GIT or QFT-PLUS) in our hospital for an employment
check-up, only nine had indeterminate results. This extremely low rate of indeterminate
results among healthy controls in our study seems to be similar to that of a recent publica-
tion that reported an indeterminate rate of 0.1% with QFT-GIT tests in healthcare workers,
emphasizing that an indeterminate IGRA result in immunocompetent individuals is very
rare in standardized and quality-assured laboratory settings [20]. Therefore, the result from
our study corroborates that indeterminate results are apparently linked to the presence of
rheumatic diseases.
Considering that there is disagreement whether the use of an immunosuppressive
agent is associated with an indeterminate IGRA result, a detailed analysis was under-
taken to evaluate factors associated with this result. On evaluating the characteristics of the
eleven patients with indeterminate results, we found that two of them (18.2%) were naïve to
medications, while the remaining (81.8%) were on medications to treat underlying diseases.
However, the logistic regression analysis revealed that glucocorticoid and immunosuppres-
sive agent usage was not an independent predictive factor for indeterminate results. These
results, at least in part, imply that the effect of drugs may not have a significant effect on
indeterminate results among patients with rheumatic diseases.
A comparison of IGRA results between the QFT-GIT and QFT-PLUS groups showed
that there was no significant difference observed regarding the results of both QFT tests.
Subsequently, indeterminate results were shown to be inversely affected by lymphocyte
counts and albumin levels. Interestingly, when adopting the optimal cut-off values for
lymphocyte counts and albumin levels, it was found that the RR was significantly high
for those with a lymphocyte count of ≤810/mm3 (RR 14.072) and an albumin level of
≤3.7 mg/dL (RR 12.041). Furthermore, for those with both lymphocyte counts and albumin
levels below the cut-off limits, the RR was over 17 times higher. Accordingly, it could be
suggested that attending physicians should be conscious of an indeterminate IGRA result
being reported when lymphopenia or hypoalbuminemia is present.
Two possible interpretations could be considered regarding the association of lym-
phocyte counts and albumin levels with indeterminate IGRA results. First, indeterminate
results of QFT-GIT and QFT-PLUS tests are usually affected by the decrease in IFN-γ
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production in the Mitogen tube or an increase in the Nil tube. Therefore, comparable
results of QFT-GIT and QFT-PLUS tests may be due to the altered IFN-γ production in
the Mitogen and Nil tubes in patients with rheumatic diseases. Given that IFN-γ is pre-
dominantly produced by T lymphocytes [21], diminished lymphocyte counts could be
related to the decrease in IFN-γ production in Mitogen tubes, which leads to a higher
probability of indeterminate results. This hypothesis is further supported by the fact that
HIV-infected individuals with low CD4+ T cell counts have a high rate of indeterminate
results [22,23]. Conversely, IFN-γ is a representative inflammatory cytokine, and albumin
is an acute phase reactant that decreases in inflammation [24,25]. While increased IFN-γ
production in the Nil tube represents a heightened systemic inflammatory process and
causes indeterminate IGRA results, a reduction in the albumin level may indicate the
severity of ongoing inflammation. Notably, a previous publication showed that a lower
albumin level was related to indeterminate IGRA results [26]. Likewise, our results seem
to be consistent with the literature that insists that both lymphocyte counts and albumin
levels are important factors linked to indeterminate results in routine clinical practice [27].
Nonetheless, since pathophysiological evaluation leading to indeterminate results was
not performed in this study, further investigations are essential in the future to better
understand this phenomenon.
Several issues should be addressed as a limitation of this study. First, our study was
retrospective in nature. Therefore, the collection of disease activity indices in rheumatic
diseases (i.e., SLE Disease Activity Index for SLE, and Disease Activity Score 28 for RA)
was not possible. In addition, indications for the QFT-GIT and QFT-PLUS tests may not
be identical and might be subject to selection bias. Second, medications used to treat
rheumatic diseases and disease activity could also influence the peripheral lymphocyte
counts and affect the IGRA results. Third, due to the diversity of rheumatic diseases
included in this study, we were not able to estimate the relative severity of the respective
diseases precisely and assess the impact of the primary diagnosis on indeterminate results.
Therefore, prospective studies with a large number of patients are necessary to better
elucidate the factors affecting indeterminate IGRAs.
5. Conclusions
In conclusion, we found that the diagnostic performance between the QFT-GIT and
QFT-PLUS tests was comparable in patients with rheumatic diseases. However, in clear
contrast to healthy controls, patients with rheumatic diseases more frequently had inde-
terminate results. Additionally, a decreased lymphocyte count and albumin level should
be recognized as factors contributing to indeterminate IGRA results, requiring careful
consideration when providing rheumatological care.
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